Phase 3 Recruiting Network
This phase III trial compares the effect of adding levocarnitine to standard chemotherapy versus (vs.) standard chemotherapy alone in protecting the liver in patients with leukemia or lymphoma. Asparaginase is part of the standard of care …
Sponsor: Children's Oncology Group
NCT ID: NCT05602194
Sites in Florida: - Golisano Children's Hospital of Southwest Florida — Fort Myers, Florida
- UF Health Cancer Institute - Gainesville — Gainesville, Florida
- Memorial Regional Hospital/Joe DiMaggio Children's Hospital — Hollywood, Florida
- Nemours Children's Clinic-Jacksonville — Jacksonville, Florida
- Nicklaus Children's Hospital — Miami, Florida
Phase 3 Recruiting Industry
This study will compare the effects of Quizartinib versus placebo in combination with chemotherapy in participants with newly diagnosed FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) negative acute myeloid leukemia (AM…
Sponsor: Daiichi Sankyo
NCT ID: NCT06578247
Sites in Florida: - Mayo Clinic Hospital — Jacksonville, Florida
- Florida Hospital Cancer Institute - Kissimmee — Kissimmee, Florida
- Tampa General Hospital — Tampa, Florida
- Moffitt Cancer Center — Tampa, Florida
Phase 3 Recruiting Academic/Other
A study to evaluate if the randomized addition of venetoclax to a chemotherapy backbone (fludarabine/cytarabine/gemtuzumab ozogamicin \[GO\]) improves survival of children/adolescents/young adults with acute myeloid leukemia (AML) in 1st r…
Sponsor: PedAL BCU, LLC
NCT ID: NCT05183035
Sites in Florida: - Golisano Children's Hospital of Southwest Florida — Fort Myers, Florida
- University of Florida Health Shands Children's Hospital — Gainesville, Florida
- Nemours Children's Specialty Care Jacksonville — Jacksonville, Florida
- Nemours Children's Hospital - Orlando — Orlando, Florida
- Saint Joseph's Hospital - Tampa — Tampa, Florida
Phase 3 Recruiting Industry
The goal of this study is to evaluate nemtabrutinib compared with investigator's choice of ibrutinib or acalabrutinib in participants with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have not received any prior …
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136559
Sites in Florida: - Clermont Oncology Center ( Site 0046) — Clermont, Florida
- Florida Cancer Specialists - South ( Site 7001) — Fort Myers, Florida
- Florida Cancer Specialists - East ( Site 7002) — West Palm Beach, Florida
Phase 3 Recruiting Industry
Ziftomenib is an investigational drug in development for the treatment of patients with acute myeloid leukemia (AML) with eligible genetic alterations. Ziftomenib is a type of therapy known to target the menin pathway in cancer cells. This…
Sponsor: Kura Oncology, Inc.
NCT ID: NCT07007312
Sites in Florida: - University of Miami — Miami, Florida
- Moffitt Cancer Center & Research Institute — Tampa, Florida
Phase 3 Recruiting Industry
Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study is to assess the safety of venetoclax in combination with obinutuzumab or acalabrutinib in the treatment of CLL. Adverse even…
Sponsor: AbbVie
NCT ID: NCT06428019
Sites in Florida: - Malcolm Randall V.A. Medical Center /ID# 267825 — Gainesville, Florida
- Cancer Specialists of North Florida - Jacksonville - AC Skinner Parkway /ID# 266713 — Jacksonville, Florida
- Mid Florida Hematology And Oncology Center /ID# 269159 — Orange City, Florida
- Comprehensive Hematology Oncology /ID# 267644 — St. Petersburg, Florida
Phase 2, Phase 3 Recruiting Industry
Study ASTX030-01 is a multi-phase study comprising of Phases 1-3 Monotherapy arms, and Phase 1 and Phase 2 Combination Therapy arms. Phase 1 Monotherapy consists of an open-label Dose Escalation Stage (Stage A) using multiple cohorts at es…
Sponsor: Taiho Oncology, Inc.
NCT ID: NCT04256317
Sites in Florida: - University of Miami - Sylvester Comprehensive Cancer Center — Miami, Florida
Phase 3 Recruiting Industry
The purpose of this study is to investigate the efficacy and safety of BGB-16673 compared with investigator's choice (idelalisib plus rituximab \[for CLL only\] or bendamustine plus rituximab or venetoclax plus rituximab retreatment) in pa…
Sponsor: BeOne Medicines
NCT ID: NCT06846671
Sites in Florida: - Florida Oncology and Hematology — Fort Myers, Florida
- Baptist Md Anderson Cancer Center — Jacksonville, Florida
- Cleveland Clinic Florida — Weston, Florida
Phase 3 Recruiting Industry
The purpose of Part 1 of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL; participants may or may not have already had treatment for their cancer. The purpose of Part …
Sponsor: Loxo Oncology, Inc.
NCT ID: NCT05254743
Sites in Florida: - Florida Cancer Specialists — Fort Myers, Florida
- Cancer Specialists of North Florida -St Augustine — Saint Augustine, Florida
- Florida Cancer Specialists East — West Palm Beach, Florida
Phase 3 Recruiting Industry
The purpose of this study is to assess the safety and tolerability and to confirm the dose of nemtabrutinib in combination with venetoclax in participants with R/R CLL/SLL. The primary study hypotheses are that the combination of nemtabrut…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT05947851
Sites in Florida: - Memorial Hospital West ( Site 5410) — Pembroke Pines, Florida
Phase 2 Recruiting NIH
This MyeloMATCH Master Screening and Reassessment Protocol (MSRP) evaluates the use of a screening tool and specific laboratory tests to help improve participants' ability to register to clinical trials throughout the course of their myelo…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564390
Sites in Florida: - UF Health Cancer Institute - Gainesville — Gainesville, Florida
- Mayo Clinic in Florida — Jacksonville, Florida
- Miami Cancer Institute — Miami, Florida
- Memorial Hospital West — Pembroke Pines, Florida
Phase 2 Recruiting NIH
This phase II trial studies how well inotuzumab ozogamicin and blinatumomab with or without ponatinib work in treating patients with CD22-positive B-lineage acute lymphoblastic leukemia that is newly diagnosed, has come back after a period…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03739814
Sites in Florida: - Holy Cross Hospital — Fort Lauderdale, Florida
- Jupiter Medical Center — Jupiter, Florida
Phase 2 Recruiting NIH
This phase II MyeloMATCH treatment trial tests whether the standard approach of cytarabine and daunorubicin in comparison to the following experimental regimens works to shrink cancer in patients with high risk acute myeloid leukemia (AML)…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05554406
Sites in Florida: - Mayo Clinic in Florida — Jacksonville, Florida
- Miami Cancer Institute — Miami, Florida
Phase 2 Recruiting NIH
This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04546399
Sites in Florida: - Golisano Children's Hospital of Southwest Florida — Fort Myers, Florida
- University of Florida Health Science Center - Gainesville — Gainesville, Florida
- Memorial Regional Hospital/Joe DiMaggio Children's Hospital — Hollywood, Florida
- Nemours Children's Clinic-Jacksonville — Jacksonville, Florida
- AdventHealth Orlando — Orlando, Florida
Phase 2 Recruiting NIH
This phase II MyeloMATCH treatment trial compares cytarabine with daunorubicin versus cytarabine with daunorubicin and venetoclax versus venetoclax with azacitidine for the treatment of younger patients with intermediate risk acute myeloid…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05554393
Sites in Florida: - Miami Cancer Institute — Miami, Florida
- Memorial Hospital West — Pembroke Pines, Florida
Phase 1, Phase 2 Recruiting Academic/Other
This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back a…
Sponsor: PedAL BCU, LLC
NCT ID: NCT04726241
Sites in Florida: - Broward Health Medical Center — Fort Lauderdale, Florida
- Golisano Children's Hospital of Southwest Florida — Fort Myers, Florida
- UF Health Cancer Institute - Gainesville — Gainesville, Florida
- Memorial Regional Hospital/Joe DiMaggio Children's Hospital — Hollywood, Florida
- Nemours Children's Clinic-Jacksonville — Jacksonville, Florida
Phase 2 Recruiting NIH
This phase II trial tests the addition of venetoclax and/or blinatumomab to usual chemotherapy for treating infants with newly diagnosed acute lymphoblastic leukemia (ALL) with a KMT2A gene rearrangement (KMT2A-rearranged \[R\]) or without…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06317662
Sites in Florida: - UF Health Cancer Institute - Gainesville — Gainesville, Florida
- Memorial Regional Hospital/Joe DiMaggio Children's Hospital — Hollywood, Florida
- Nemours Children's Clinic-Jacksonville — Jacksonville, Florida
- University of Miami Miller School of Medicine-Sylvester Cancer Center — Miami, Florida
- AdventHealth Orlando — Orlando, Florida
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2, open-label, multicenter study to determine the efficacy and safety of JCAR017 in adult subjects with relapsed or refractory CLL or SLL. The study will include a Phase 1 part to determine the recommended dose of JCAR017…
Sponsor: Juno Therapeutics, a Subsidiary of Celgene
NCT ID: NCT03331198
Sites in Florida: - Mayo Clinic - Jacksonville — Jacksonville, Florida
- Mayo Clinic — Jacksonville, Florida
Phase 2 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of ibrutinib + venetoclax (I+V) and ibrutinib monotherapy regimens in which dosing of ibrutinib is either proactively reduced or reactively modified in response to adverse ev…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT05963074
Sites in Florida: - Mount Sinai Medical Center Campus — Miami Beach, Florida
- The Oncology Institute — North Miami Beach, Florida
- Mid Florida Hematology Oncology — Orange, Florida
Phase 2 Recruiting Industry
This study will be divided into 2 parts (Part 1 and Part 2). Part 1 will evaluate 2 doses of tagraxofusp (9 and 12 micrograms/kilogram/day \[μg/kg/day\]), used in combination with venetoclax and azacitidine, to determine the dose for Part …
Sponsor: Stemline Therapeutics, Inc.
NCT ID: NCT06456463
Sites in Florida: - University of Miami — Miami, Florida
- AdventHealth Cancer Institute — Orlando, Florida
Phase 2 Recruiting Industry
The main purpose of Part 1 of this study is to assess the efficacy and safety of 3 dose levels of Pirtobrutinib in participants with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), who have received 1-3 lines of tre…
Sponsor: Loxo Oncology, Inc.
NCT ID: NCT06588478
Sites in Florida: - University of Miami Hospital and Clinics, Sylvester Cancer Center — Miami, Florida
Phase 1, Phase 2 Recruiting Academic/Other
This screening and multi-sub-study Phase 1b/2 trial will establish a method for genomic screening followed by assigning and accruing simultaneously to a multi-study "Master Protocol (BAML-16-001-M1)." The specific subtype of acute myeloid …
Sponsor: Beat AML, LLC
NCT ID: NCT03013998
Sites in Florida: - University of Florida Health Shands Cancer Hospital — Gainesville, Florida
- Mayo Clinic Florida — Jacksonville, Florida
Phase 1, Phase 2 Recruiting Academic/Other
This clinical trial will test the safety and efficacy of combining trametinib and azacitidine in patients with juvenile myelomonocytic leukemia (JMML). Newly diagnosed lower-risk JMML patients will receive trametinib and azacitidine. High-…
Sponsor: Therapeutic Advances in Childhood Leukemia Consortium
NCT ID: NCT05849662
Sites in Florida: - University of Miami — Miami, Florida
Phase 1, Phase 2 Recruiting Industry
The goal of the study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of TERN-701, a highly selective allosteric inhibitor of BCR-ABL1, in participants with previously treated chronic phase - chroni…
Sponsor: Terns, Inc.
NCT ID: NCT06163430
Sites in Florida: - Florida Cancer Specialists - South Region Research Office — Fort Myers, Florida
- Florida Cancer Affiliates - Ocala — Ocala, Florida
- Florida Cancer Specialists - North Region Research Office — St. Petersburg, Florida
- Florida Cancer Specialists - East Region Research Office — West Palm Beach, Florida
Phase 2 Recruiting Industry
The goal of this clinical trial is to learn if participants treated with the experimental drug cusatuzumab added to venetoclax and azacitidine works to treat acute myeloid leukemia (AML) compared to venetoclax and azacitidine. Venetoclax a…
Sponsor: OncoVerity, Inc.
NCT ID: NCT06384261
Sites in Florida: - AdventHealth Medical Group Blood & Marrow Transplant at Orlando — Orlando, Florida